Form 4: Repare Therapeutics Inc. Executive Steve Forte Reports Stock Option Grant and RSU Award
SEC Form 4 Filing
EVP and CFO of Repare Therapeutics, Steve Forte, reports the acquisition of stock options and restricted stock units (RSUs) in the company.
Summary
- On March 1, 2024, Steve Forte, the EVP and Chief Financial Officer of Repare Therapeutics Inc., reported transactions involving the company's securities.
- Forte acquired 14,000 common shares through a restricted stock unit (RSU) award.
- These RSUs will vest in three equal installments on March 1, 2025, March 1, 2026, and March 1, 2027, contingent upon continued service.
- Additionally, Forte acquired an option to purchase 85,000 common shares at an exercise price of $6.95.
- 25% of these options will vest on March 1, 2025, with the remaining shares vesting monthly thereafter over 36 months, also subject to continued service.
- Following these transactions, Forte directly owns 44,687 common shares and holds options for 85,000 shares.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The grants incentivize the executive but don't inherently signal positive or negative company performance.
Positives
- The grant of stock options and RSUs to a key executive like the CFO can be seen as an incentive to align their interests with the long-term success of the company.
Future Outlook
The vesting schedules for the RSUs and stock options are contingent upon the Reporting Person's continued service with the company.
Industry Context
Stock options and RSU grants are common compensation practices for executives in publicly traded companies, particularly in the biotech and pharmaceutical industries, to incentivize performance and align executive interests with shareholder value.
Stakeholder Impact
- Shareholders may view the equity grants as a positive incentive for the CFO to contribute to the company's long-term success.
- Employees may see the grants as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of transaction: RSU award and stock option grant. |
| 03/04/2024 | Date of Form 4 filing. |
| 03/01/2025 | First vesting date for both RSUs (33 1/3%) and stock options (25%). |
| 03/01/2026 | Second vesting date for RSUs (33 1/3%). |
| 03/01/2027 | Final vesting date for RSUs (33 1/3%). |
| 02/28/2034 | Expiration date for the employee stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.